Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of ...

VRTX to Stop Further Development of VX-264 in T1D. Vertex is evaluating VX-264 ... estimates for Jazz Pharmaceuticals’ earnings per share have increased from $22.06 to $23.33 for 2025.

Vertex Pharmaceuticals Incorporated VRTX announced data on the first patient from an ongoing phase I/II study evaluating its investigational cell-based therapy, VX-880 for the treatment of type I ...

Analyst Alexandria Hammond of Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $550.00. Alexandria Hammond’s rating ...

Vertex to initiate a Phase 1/2 clinical trial in the coming months – – VX-264 is the second investigational program in Vertex’s pipeline containing stem cell-derived, fully differentiated ...

Vertex Pharmaceuticals (VRTX 0.73%) ... (T1D) called VX-880. On Oct. 18, the company gave an update on the first patient dosed with VX-880 in a phase 1/2 clinical trial for the treatment.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...

Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D) - Vertex will initiate a Phase 1/2 clinical ...

On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel ...